FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 655 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Stringently Defined Clinical Complete Response After Gemcitabine, Cisplatin, Plus Nivolumab Facilitates... October 18, 2023 Long-Term Benefit of Sotorasib in Patients with Pretreated KRASG12C-Mutated NSCLC May 15, 2023 Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor... March 26, 2024 Μελάνωμα και καλοκαίρι. Πώς να προφυλαχθείτε July 16, 2019 Load more HOT NEWS Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests Liquid Biopsies for Cancer: What to Know and What to Expect Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with... Researchers at Purdue Create Filler That May Help Regenerate Tissue in...
